The global biobanking market was valued at USD 64.3 Billion in 2024 and is projected to reach USD 101.1 Billion by 2033, growing at a CAGR of 5.2% during 2025-2033. The market expansion is driven by growing demand for high-quality biospecimens, advances in genomics and proteomics, and increasing focus on personalized medicine. North America leads with over 34% market share in 2024, supported by rising genomic research activities and chronic disease prevalence. The integration of advanced digital platforms and collaborations in biobanking bolster efficiency and innovation globally.
STUDY ASSUMPTION YEARS
- Base Year: 2024
- Historical Years: 2019-2024
- Forecast Period: 2025-2033
BIOBANKING MARKET KEY TAKEAWAYS
- Current Market Size (2024): USD 64.3 Billion
- CAGR (2025-2033): 5.2%
- Market Forecast Year: 2033
- North America dominates with over 34% market share in 2024.
- Blood products are the leading specimen type due to their role in medical research and diagnostics.
- Disease-oriented biobanks lead by biobank type, focusing on specific disease samples for precision medicine.
- Research is the largest application segment, driving therapeutic and biomarker development.
- Pharma and biotech companies hold 58.3% of the market share among end-users, leveraging biobanks for drug development.
Sample Request Link:
https://www.imarcgroup.com/biobanking-market/requestsample
MARKET GROWTH FACTORS
The biobanking market growth is propelled by increasing demand for high-quality biological samples in medical research and personalized medicine. Advances in genomics and proteomics have heightened the need for well-maintained biospecimens essential for drug discovery, disease diagnosis, and biomarker development. Notably, government and private investments in biobanking infrastructure, alongside the focus on regenerative medicine, further support this expansion. The integration of automated sample management systems enhances operational efficiency, reliability, and sample integrity, contributing significantly to market growth.
The rising prevalence of chronic diseases such as cancer, diabetes, cardiovascular conditions, and respiratory disorders globally is driving demand for biospecimens. The World Health Organization reports that chronic diseases account for 41 million deaths annually, constituting 74% of all global fatalities. This critical health burden necessitates the development of diagnostics and therapies based on biospecimen research. Consequently, there is increasing demand for assays for genetic testing and biospecimens from clinical laboratories, which remains a lucrative growth opportunity.
Digital biobanking technologies, including virtual biobanks and AI-powered management solutions, are transforming the market by enabling better data management and accessibility. The adoption of digital platforms for remote sample tracking and real-time validation ensures enhanced transparency and sample quality. Virtual biobanks eliminate geographical and logistical barriers, facilitating seamless researcher access to biospecimens globally. Such technological advancements improve compliance, scalability, and operational efficiency, accelerating market growth through innovations in clinical research and therapeutics.
MARKET SEGMENTATION
Analysis by Specimen Type:
- Blood Products: Includes plasma, serum, and whole blood; pivotal in medical research, diagnostics, and therapeutic innovation. Crucial for studying biomarkers and disease mechanisms, especially in chronic diseases and infectious conditions.
- Solid Tissue: Not provided in source.
- Cell Lines: Not provided in source.
- Nucleic Acid: Not provided in source.
- Others: Not provided in source.
Analysis by Biobank Type:
- Population-based Biobanks: Not provided in source.
- Disease-oriented Biobanks: Focused on disease-specific samples like cancer and cardiovascular diseases; critical for precision medicine and tailored therapies.
Analysis by Application:
- Therapeutics: Not provided in source.
- Research: Dominant segment driven by biobanks supporting genomics, biomarker discovery, and drug development by providing high-quality biospecimens.
Analysis by End-User:
- Academic Institutions: Not provided in source.
- Pharma and Biotech Companies: Leading segment with about 58.3% market share in 2024, relying on biospecimens for therapeutic validation and drug development.
REGIONAL INSIGHTS
North America is the dominant region, holding over 34% market share in 2024. The region benefits from advanced healthcare infrastructure, significant R&D investments, and a strong focus on precision medicine. Robust biobank networks support genomic and disease-specific research, enhanced by private and government funding. Adoption of automated biobank management and AI-driven analytics enhances sample preservation and data integration, accelerating research outcomes for chronic diseases such as cancer and cardiovascular conditions.
RECENT DEVELOPMENTS & NEWS
- October 2024: NABL launched a new Accreditation Programme for Biobanking aligned with ISO 20387:2018 to ensure quality and traceability of biological materials in research.
- July 2024: Amazon Web Services announced USD 8.7 Million in cloud computing credits to UK Biobank for AI and machine learning data processing, matched by government funding.
- May 2024: CHA Bio Group and CIC signed an MoU to establish an open innovation centre focused on Cell Gene Biobank (CGB) in Pangyo 2nd Techno Valley, fostering biotech innovation ecosystem.
KEY PLAYERS
- Brooks Automation Inc.
- Bay Biosciences LLC
- Boca Biolistics
- Ctibiotech
- Cureline Inc.
- Firalis
- Greiner Bio-One International GmbH
- Hamilton Company
- Merck KGaA
- ProteoGenex Inc.
- Thermo Fisher Scientific Inc.
- VWR Corporation (Avantor Inc.)
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
ABOUT US
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
CONTACT US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201971-6302
Comments (0)